Departments of Obstetrics and Gynecology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, and Academic Medical Centre, Amsterdam, the Netherlands; the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia; the Department of Obstetrics and Gynaecology, Martini Hospital Groningen, Groningen, and the Department of Obstetrics and Gynecology, Maastricht University Medical Center, Maastricht, the Netherlands; Clinical and Population Perinatal Health Research, Kolling Institute, University of Sydney at Royal North Shore Hospital, St. Leonards, and Clinical and Population Perinatal Health Research, Kolling Institute, University of Sydney, Sydney, New South Wales, and Paediatrics and Reproductive Health, University of Adelaide, Adelaide, South Australia, Australia.
Corresponding author: Johanna Quist-Nelson, MD, Department of Obstetrics and Gynecology, Thomas Jefferson University Hospital, 833 Chestnut Street, Mezzanine Level, Philadelphia, PA 19107; email: [email protected].
Ben W. Mol is supported by a NHMRC Practitioner Fellowship (GNT1082548).
Financial Disclosure Dr. van der Ham was first author on both of the PPROMEXIL trials. Dr. Morris was the first author of the PPROMT study. Dr. Mol has been a consultant for ObsEva, Merck, and Guerbet. The other authors did not report any potential conflicts of interest.
Presented at 16th Fetal Medicine Foundation World Congress, June 25–29, 2017, Ljubljana, Slovenia.
The authors thank the contributors of PPROMEXIL, PPROMEXIL-2, PPROMT. For a list of contributors to the PPROMEXIL and PPROMEXIL-2 trials and a list of contributors to the PPROMT trial, see Appendix 1, available online at http://links.lww.com/AOG/B57.
The authors thank Gary Kaplan for librarian assistance with the systematic review.
Each author has indicated that he or she has met the journal's requirements for authorship.